Qinghe Zeng, Christophe Klein, Stefano Caruso, Pascale Maille, Daniela S Allende, Beatriz Mínguez, Massimo Iavarone, Massih Ningarhari, Andrea Casadei-Gardini, Federica Pedica, Margherita Rimini, Riccardo Perbellini, Camille Boulagnon-Rombi, Alexandra Heurgué, Marco Maggioni, Mohamed Rela, Mukul Vij, Sylvain Baulande, Patricia Legoix, Sonia Lameiras, Léa Bruges, Viviane Gnemmi, Jean-Charles Nault, Claudia Campani, Hyungjin Rhee, Young Nyun Park, Mercedes Iñarrairaegui, Guillermo Garcia-Porrero, Josepmaria Argemi, Bruno Sangro, Antonio D'Alessio, Bernhard Scheiner, David James Pinato, Matthias Pinter, Valérie Paradis, Aurélie Beaufrère, Simon Peter, Lorenza Rimassa, Luca Di Tommaso, Arndt Vogel, Sophie Michalak, Jérôme Boursier, Nicolas Loménie, Marianne Ziol, Julien Calderaro
BACKGROUND: Clinical benefits of atezolizumab plus bevacizumab (atezolizumab-bevacizumab) are observed only in a subset of patients with hepatocellular carcinoma and the development of biomarkers is needed to improve therapeutic strategies. The atezolizumab-bevacizumab response signature (ABRS), assessed by molecular biology profiling techniques, has been shown to be associated with progression-free survival after treatment initiation. The primary objective of our study was to develop an artificial intelligence (AI) model able to estimate ABRS expression directly from histological slides, and to evaluate if model predictions were associated with progression-free survival...
November 8, 2023: Lancet Oncology